SCHEMBL2804910

SCHEMBL2804910

CCc1ccccc1-c1ccc(-c2nc(-c3ccc(C(=O)OC)c(F)c3)no2)cc1COC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 13/20 0.68
S1PR3 Q99500 2/20 0.68
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
TSHR P16473 2/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
HAVCR2 Q8TDQ0 1/20 0.39
TP53 P04637 1/20 0.39
RARA P10276 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772309 0.96 S1PR1 (0.70) S1PR1S1PR3NPC1RAB9AMAPT
SCHEMBL2772469 0.94 S1PR1 (0.69) S1PR1S1PR3NPC1RAB9AMAPT
SCHEMBL9928648 0.93 S1PR1 (0.79) S1PR1S1PR3NPC1RAB9AALDH1A1
SCHEMBL411050 0.92 S1PR1 (0.81) S1PR1S1PR3NPC1RAB9A
SCHEMBL2774322 0.91 S1PR1 (0.66) S1PR1S1PR3NPC1RAB9AMAPT
SCHEMBL2772117 0.91 S1PR1 (0.66) S1PR1S1PR3NPC1RAB9AMAPT
SCHEMBL2773519 0.91 S1PR1 (0.63) S1PR1S1PR3NPC1RAB9AMAPT
SCHEMBL2773257 0.90 S1PR1 (0.70) S1PR1S1PR3NPC1RAB9ARARA
SCHEMBL2774451 0.90 S1PR1 (0.64) S1PR1S1PR3NPC1RAB9A
SCHEMBL2773884 0.89 S1PR1 (0.81) S1PR1S1PR3NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 S1PR1 483/4885S1PR3 335/4885NPC1 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.